News archive
Showing 767 results
November 2018
-
Media Release
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
- Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2… -
Media Release
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
October 2018
-
Media Release
Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
-- Kymriah was the first CAR-T cell therapy to ever be approved by a regulatory authority-- Since 1970, more than 40 Novartis innovative therapies have been recognized by the Prix Galien Foundation… -
Media Release
Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
-
Media Release
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central… -
Media Release
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
-
Media Release
Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
New data show that 73% of ankylosing spondylitis (AS) patients taking Cosentyx® (secukinumab) achieved improvement in AS signs and symptoms at four years, with sustained ASAS response rates1 AS is a… -
Media Release
Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
-
Media Release
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis,… -
Media Release
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
-
Media Release
Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients
- There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of… -
Media Release
Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients